Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Debt (2016 - 2025)

IGC Pharma (IGC) has disclosed Total Debt for 16 consecutive years, with $132000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt fell 2.22% to $132000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $132000.0, a 2.22% decrease, with the full-year FY2025 number at $134000.0, down 2.19% from a year prior.
  • Total Debt was $132000.0 for Q3 2025 at IGC Pharma, down from $133000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $580000.0 in Q1 2021 to a low of $132000.0 in Q3 2025.
  • A 5-year average of $163263.2 and a median of $140000.0 in 2023 define the central range for Total Debt.
  • Biggest YoY gain for Total Debt was 1060.0% in 2021; the steepest drop was 76.19% in 2021.
  • IGC Pharma's Total Debt stood at $148000.0 in 2021, then decreased by 4.73% to $141000.0 in 2022, then fell by 2.13% to $138000.0 in 2023, then dropped by 2.9% to $134000.0 in 2024, then dropped by 1.49% to $132000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Total Debt are $132000.0 (Q3 2025), $133000.0 (Q2 2025), and $134000.0 (Q1 2025).